这组数据的价值在于 "三细胞系对照" 的完整性: MCF-7 与 T47D 均为 ER 阳性乳腺癌细胞,MDA-MB-231 为 ER 阴性三阴性乳腺癌细胞。他莫昔芬能抑制前两者却对后者无效,直接证明其抑制作用依赖 ER 表达 —— 这是 SERM 类化合物最有效的机制验证方式,也提示任何使用他莫昔芬的细胞实验都应先确认细胞系的 ER 状态。
[1]. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998 Nov 26;339(22):1609-18. [2]. Hawariah A, et al. In vitro response of human breast cancer cell lines to the growth-inhibitory effects of styrylpyrone derivative (SPD) and assessment of its antiestrogenicity. Anticancer Res. 1998 Nov-Dec;18(6A):4383-6. [3]. Nagai J, et al. Hyperactivity with disrupted attention by activation of an astrocyte synaptogenic cue. Cell. 2019 May 16;177(5):1280-1292.e20. [4]. Zhao R, et al. Tamoxifen enhances the Hsp90 molecular chaperone ATPase activity. PLoS One. 2010 Apr 1;5(4):e9934. [5]. Kedjouar B, et al. Molecular characterization of the microsomal tamoxifen binding site. J Biol Chem. 2004 Aug 6;279(32):34048-61. [6]. Feil S, et al. Inducible Cre mice. Methods Mol Biol. 2009;530:343-63. [7]. Kim H, et al. Mouse Cre-LoxP system: general principles to determine tissue-specific roles of target genes. Lab Anim Res. 2018 Dec;34(4):147-159. [8]. Bi Q, et al. Microglia-derived PDGFB promotes neuronal potassium currents to suppress basal sympathetic tonicity and limit hypertension. Immunity. 2022 Aug 9;55(8):1466-1482.e9. [9]. Chen MY, et al. A review of tamoxifen administration regimen optimization for Cre/loxp system in mouse bone study. Biomed Pharmacother. 2023 Sep;165:115045. [10]. El-Beshbishy HA. Hepatoprotective effect of green tea (Camellia sinensis) extract against tamoxifen-induced liver injury in rats. J Biochem Mol Biol. 2005 Sep 30;38(5):563-70. [11]. El-Beshbishy HA. The effect of dimethyl dimethoxy biphenyl dicarboxylate (DDB) against tamoxifen-induced liver injury in rats: DDB use is curative or protective. BMB Reports. 2005;38(3):300-306. [12]. Reid JM, et al. Pharmacokinetics of endoxifen and tamoxifen in female mice: implications for comparative in vivo activity studies. Cancer Chemother Pharmacol. 2014 Dec;74(6):1271-8. [13]. Kim CS, et al. Effects of silybinin on the pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen in rats. Anticancer Res. 2010 Jan;30(1):79-85.